Announced the commercial option of Epoprostenol for Injection today.

Food and Medication Administration for the treatment of moderate to severe PAH. Unlike various other epoprostenol formulations, Epoprostenol for Injection is certainly stable at room heat range for up to a day when diluted and put into the pump for administration, eliminating the need for ice packs. Related StoriesLenvatinib trial offers expect thyroid tumor patientsUsing breath testing to diagnose liver diseases: an interview with Larry CohenKidney failure predictors in adolescents: an interview with Dr. Per-Ola SundinAccredo Wellness Group, Inc., a wholly-owned subsidiary of Medco Wellness Solutions, Inc., will serve as the sole specialty pharmacy company of Epoprostenol for Injection.Patent ARC Pharmaceuticals Inc. announced today that The University of British Columbia offers been granted a new US patent entitled Pharmaceutical Compositions and Methods Associated with Fucans, No. 6,812,220. The patent protects key intellectual property exclusively licensed to ARC that may be used in the advancement of ARC’s lead product candidates for the treating surgical adhesions. This released patent strengthens ARC’s intellectual property portfolio, stated Dr. Chuck Winternitz, Director of Procedures for ARC. The polymers included broaden the Company’s pipeline and may end up being useful in the advancement of films, instillates and gels for the treating surgical adhesion disease.